Small cell lung cancer (SCLC), often known as the “king of lung cancer,” has long relied on the EP regimen (cisplatin plus etoposide) as the foundation of first-line therapy for nearly three decades. Although recent years have seen the introduction of immunotherapy combined with chemotherapy, which has brought incremental survival benefits, long-term outcomes for patients remain limited. At the 2025 ASCO Annual Meeting, Dr. Yan Huang from Sun Yat-sen University Cancer Center presented the results of a Phase I study (Abstract #3002) on BL-B01D1, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, in patients with SCLC who had failed standard treatments. The study showed that in patients who progressed after first-line chemo-immunotherapy, BL-B01D1 achieved a median overall survival (OS) of 15.1 months and a confirmed objective response rate (ORR) of 75%—breakthrough data that may offer a potential new treatment option for this hard-to-treat disease. Oncology Frontier invited Dr. Huang to provide an in-depth interpretation of the study’s clinical significance and application prospects.
